Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 11.5% Higher – Time to Buy?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shot up 11.5% during trading on Monday . The company traded as high as $0.45 and last traded at $0.43. 54,448,846 shares traded hands during trading, a decline of 37% from the average session volume of 86,044,078 shares. The stock had previously closed at $0.38.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Saturday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The firm has a market cap of $78.87 million, a PE ratio of -0.01 and a beta of 2.02. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The business has a 50 day simple moving average of $0.28 and a two-hundred day simple moving average of $0.28.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. As a group, equities research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals as of its most recent SEC filing. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.